Add to ORKGCurrently, there are no reliable ex vivo models that predict anticancer drug responses in human tumors accurately. A comprehensive method of mimicking a 3D microenvironment to study effects of anticancer drugs on specific cancer types is essential. Here, we report the development of a three-dimensional microfluidic cell array (3D μFCA), which reconstructs a 3D tumor microenvironment with cancer cells and microvascular endothelial cells. To mimic the in vivo spatial relationship between microvessels and nonendothelial cells embedded in extracellular matrix, three polydimethylsiloxane (PDMS) layers were built into this array. The multilayer property of the device enabled the imitation of the drug delivery in a microtissue array with simulated...
Experiments were performed in a modified microfluidic platform recapitulating part of the in vivo tu...
In the United States, breast cancer is the first-leading cancer type in women. Current strategies to...
Research on the development of anti-cancer drugs has progressed, but the low reliability of animal e...
Currently, there are no reliable ex vivo models that predict anticancer drug responses in human tumo...
Currently, there are no reliable <i>ex vivo</i> models that predict anticancer drug responses in hum...
We developed a functional high throughput 3D microfluidic living cell array (MLC) for anti-cancer dr...
The heterogeneity of cellular microenvironments in tumors severely limits the efficacy of most cance...
Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant rol...
Today, innovative three-dimensional (3D) cell culture models have been proposed as viable and biomim...
Two‐dimensional (2D) cell cultures have been the primary screening tools to predict drug impacts in ...
The natural microenvironment of tumors is composed of extracellular matrix (ECM), blood vasculature,...
Innovative drug screening platforms should improve the discovery of novel and personalized cancer tr...
Development of high-fidelity three-dimensional (3D) models to recapitulate the tumor microenvironmen...
The discrepancies between the findings in preclinical studies, and in vivo testing and clinical tria...
A key aspect of cancer metastases is the tendency for specific cancer cells to home to defined subse...
Experiments were performed in a modified microfluidic platform recapitulating part of the in vivo tu...
In the United States, breast cancer is the first-leading cancer type in women. Current strategies to...
Research on the development of anti-cancer drugs has progressed, but the low reliability of animal e...
Currently, there are no reliable ex vivo models that predict anticancer drug responses in human tumo...
Currently, there are no reliable <i>ex vivo</i> models that predict anticancer drug responses in hum...
We developed a functional high throughput 3D microfluidic living cell array (MLC) for anti-cancer dr...
The heterogeneity of cellular microenvironments in tumors severely limits the efficacy of most cance...
Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant rol...
Today, innovative three-dimensional (3D) cell culture models have been proposed as viable and biomim...
Two‐dimensional (2D) cell cultures have been the primary screening tools to predict drug impacts in ...
The natural microenvironment of tumors is composed of extracellular matrix (ECM), blood vasculature,...
Innovative drug screening platforms should improve the discovery of novel and personalized cancer tr...
Development of high-fidelity three-dimensional (3D) models to recapitulate the tumor microenvironmen...
The discrepancies between the findings in preclinical studies, and in vivo testing and clinical tria...
A key aspect of cancer metastases is the tendency for specific cancer cells to home to defined subse...
Experiments were performed in a modified microfluidic platform recapitulating part of the in vivo tu...
In the United States, breast cancer is the first-leading cancer type in women. Current strategies to...
Research on the development of anti-cancer drugs has progressed, but the low reliability of animal e...